ABSTRACT
Prior to 1980 the only registered indication for intravenous immunoglobulin (IVIG) was primary and secondary immunodeficiency. Since 1980, however, the treatment of idiopathic thrombocytopenic purpura (ITP) has become a model for a new biological and immunomodulatory approach in the intravenous application of human immunoglobulin G (IgG) concentrate, produced from healthy blood donors.
